Neuroscience

#Allyx Therapeutics #Neurodegenerative disorders #Neuroscience #Phase I trial

Trial supports neurodegenerative disease-modifying drug

Biotechnology company Allyx Therapeutics has reported positive Phase Ib clinical data for its lead compound, ALX-001, a first-in-class, synapse-targeted, disease-modifying oral therapy in development for neurodegenerative diseases. The findings were presented at the AD/PD 2024 Conference in Lisbon. The Phase Ib study examined the… Read More

#News

#Financing #Mission Therapeutics #Neurodegenerative disorders #Neuroscience #Parkinson's

£25.2 million raised to progress Parkinson’s treatment

Mission Therapeutics has raised £25.2 ($32.1) million to accelerate development of its lead drug candidates in the area of mitophagy, MTX325 and MTX652, through clinical trials. The financing was jointly led by existing investors Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group, and Rosetta Capital. MTX325… Read More

#Business & Investment #News

#Amyotrophic lateral sclerosis (ALS) #Clinical trials #Neuroscience #NeuroSense

NeuroSense reports positive results from its ALS trial 

NeuroSense Therapeutics has reported additional positive data from its six-month double-blind Phase IIb PARADIGM trial of its lead drug candidate PrimeC for the treatment of amyotrophic lateral sclerosis (ALS).   The PARADIGM trial’s secondary clinical efficacy outcome measure endpoints included Quality of Life and Survival. Consistent with the… Read More

#News

#Amplify Therapeutics #BioInnovation Institute #Funding #Fuse Vectors #Metsystem #Parkinson's

Three companies join the BioInnovation Institute programme  

BioInnovation Institute (BII), life science incubator, has announced the addition of six companies who will receive additional financial support through its Venture House programme, created to further support former Venture Lab companies through their next phase of growth. Three of these are key to the advancement of gene therapies,… Read More

#News

Plant-based concept
#Bio Studio #Bioma #Chronic pain #Mental health #Plant-based #Start-ups

Tackling pain and mental health with plant-based medicines

DDW Editor Reece Armstrong speaks to Michael Krogh Jensen, Co-founder and CEO of Biomia, about developing plant-based medicines and what recent investment and support from the Bio Studio programme means for its pipeline. RA: How has being part of the Bio Studio programme helped you develop your pipeline? MJ: The… Read More

#Exclusive Content #Start-up Zone

Neuroscience
#Autism #Gate Neurosciences #Neurodevelopmental disorders #Neuroscience #Preclinical investigations

Preclinical studies demonstrate potential of zelquistinel in autism

Robust efficacy in several preclinical models supports high translational potential of zelquistinel in autism and reflects broader opportunity across synaptic dysfunction disorders. Gate Neurosciences has announced the publication of new peer-reviewed research demonstrating the therapeutic potential of zelquistinel (GATE-251) to address symptoms of autism spectrum disorder… Read More

#News

#Antibodies #Bispecific Antibodies #FDA #Monoclonal antibodies #Neuroscience #Oncology

New DDW Highlights podcast: 11 March 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  It was antibodies hitting the headlines this week, with the discovery of antibodies with… Read More

#News

CT scans of the brain
#Alzheimer's #Galimedix Therapeutics #Neurodegenerative disorders #Neuroscience #Preclinical investigations

New drug shows promising neuroprotective effects

Galimedix Therapeutics has announced data showing small molecule GAL-201 has neuroprotective and symptomatic alleviation potential in models of Alzheimer’s disease (AD). These new findings support previous studies where GAL-201 was characterised as a promising development candidate for the treatment of AD (Russ et. al. 2022). Read More

#News #Trending News

#Antibodies #Bispecific Antibodies #FDA #Monoclonal antibodies #Neuroscience #Oncology

This week in drug discovery (4-8 March) 

News round-up for 4-8 March by DDW Digital Content Editor Diana Spencer. It was antibodies hitting the headlines this week, with the discovery of antibodies with potential against a new influenza target, the launch of a Phase I trial to investigate a novel type of bispecific antibody, and… Read More

#News

Dementia
#Alzheimer's #Eli Lilly #FDA #Neurodegenerative disorders #Phase III trial

FDA advisory committee meeting delays approval of donanemab

The US Food and Drug Administration (FDA) has revealed plans to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) to discuss the Phase III TRAILBLAZER-ALZ 2 trial. The trial evaluated the efficacy and safety of Eli Lilly’s donanemab in early symptomatic Alzheimer's disease. The… Read More

#News #Regulatory

#Biologics / Biotechnology #Cell therapy #CNS #Financing #Kenai Therapeutics #Neurology #Parkinson's

$82m investment in cell therapies for neurological diseases

Biotechnology company Kenai Therapeutics has raised $82 million in a Series A financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group. Kenai Therapeutics previously raised seed funding under the name Ryne Bio. “We are grateful for the support of a syndicate of leading life science investors… Read More

#Business & Investment #News

A scientist examines brain scans on a large screen
#CNS #Neurology #Neuropsychiatric disorders #Neuroscience #Precision medicine #PrecisionLife

The era of precision neuroscience

Listen to this article on the DDW Podcast: Dr Steve Gardner, CEO of the computational biology company PrecisionLife, explores the challenges of achieving precision medicine in complex CNS conditions and explains how new precision neuroscience approaches are benefitting pharmaceutical companies who are again investing in the field to develop better treatments… Read More

#Exclusive Content

#FDA #Finance #GlobalData #Minerva Biosciences #Neuroscience #Schizophrenia

Minerva value plummets following FDA rejection of roluperidone

The stock market value of Minerva Biosciences has dropped nearly 60%, following the US Food and Drug administration (FDA) decision not to approve roluperidone for symptoms of schizophrenia. The company received a ‘Complete Response Letter’ from the FDA highlighting the clinical deficiencies in its new drug… Read More

#News #Trending News

#AI / data analytics / healthtech / informatics #Human disease models #Interview #Neurology #Neuroscience #Stem cells

Putting human data at the centre of drug discovery

Listen to this article on the DDW Podcast: James Peach is the Co-Founder and CEO of Human Centric Drug Discovery (HCDD), an Oxford University spin-out improving neurology drug discovery by bringing more human data to the process. Peach shared his insight with DDW’s Megan Thomas. MT: In what ways can human… Read More

#Exclusive Content #Opinion

Neuron
#ALS #Human disease models #iPSC #Neurology #Pluripotent stem cells #Stem cells #Whitepaper

Whitepaper: Explore iPSC-derived motor neuron morphology

A new whitepaper is now available from DDW and Sartorius entitled ‘iPSC-Derived Motor Neurons and Microglia From ALS Background Display Disease Phenotype’. Induced pluripotent stem cell (iPSC)-derived cells are a significant resource for disease modelling. They allow the use of cells directly from affected patients… Read More

#News

#ALS #Drug discovery #Human disease models #iPSC #Neurology #Pluripotent stem cells #Stem cells

Using patient-specific cells for disease modelling

Induced pluripotent stem cell (iPSC)-derived cells are a significant resource for disease modelling. They allow the use of cells directly from affected patients and have the potential to guide these cells towards multiple lineages. Download the whitepaper to: Explore iPSC-derived motor neuron morphology Discover how ALS disease phenotype… Read More

#Resources